According to numerous reports, HER2 bound by trastuzumab blocks the PI3K/AKT pathway and inhibits the proliferation of cancer cells’ overexpressed HER2 receptors, and the combination of trastuzumab with H9 has the potential to synergize efficacy [20,32]. Here, ERBB2 is linked to cancer.